Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Correction to: Leukemia 32, 252–262 (2018);;

published online February 2018

Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Table. Major clinical trials of next generation PIs (carfilzomib, Ixazomib), next generation IMiDs (pomalidomide) and monoclonal antibody.

Author information

Correspondence to C. S. Chim.

Ethics declarations

Conflict of interest

CSC received sponsorship and honoraria from Celgene, Amgen, Takeda, and Janssen. SKK received research funding for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, Kite, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen; served as consultants or advisory board members of Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen; and received personal honoraria from Oncopeptides, Adaptive. RZO served as advisory board member for Amgen, Bristol-Myers Squibb, Celgene, Janssen Kite Pharma, Sanofi-Aventis, and Takeda. Received research support from Amgen, BioTheryX, and Spectrum Pharma. GC received research support and honoraria from Celgene, Janssen-Cilag, and Takeda; and honoraria from Amgen, Bristol-Myers Squibb, GlycoMimetics, Seattle Genetics, Karyopharm, and Sanofi. PGR has served as a member of advisory committees to Janssen, Amgen, Celgene, Takeda, Karyopharm, and Oncopeptides, and has received research funding from Takeda, Oncopeptides, Celgene & Bristol Myers Squibb. MAG received personal fees from Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, Abbvie’s Data Safety Monitoring board, Research to Practice; receives grants and personal fees from Spectrum; received speaker fees from Teva, Johnson, and Johnson, Medscape, DAVA oncology; received royalties from Springer Publishing; received grant funding from Amyloidosis Foundation & International Waldenstrom Foundation; and served as advisory board for Pharmacyclics and Proclara outside the submitted work. SG served as advisory board members of Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceutical, Takeda, Novartis, Kite & Spectrum Pharma; received research funding from Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi & Takeda. MVM received honoraria from Janssen, Celgene, Amgen, Takeda, GSK, Abbvie, Seattle Genetics, Pharmamar for lectures and advisory boards. XL received honoraria from Celgene, Amgen, Takeda, BMS, Merck, Janssen, Karyopharm, Novartis, Gilead, Sanofi, Roche, Oncopeptides. KCA served as advisor/consultant to Celgene, Millennium-Takeda, Gilead, Janssen & Bristol Myers Squibb and served as scientific founder of Oncopep & C4 Therapeutics.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark